鉴定社区获得性肺炎患者的耐药病原体。

IF 1.8 Q3 RESPIRATORY SYSTEM Advances in respiratory medicine Pub Date : 2023-05-31 DOI:10.3390/arm91030018
Francesco Amati, Francesco Bindo, Anna Stainer, Andrea Gramegna, Marco Mantero, Mattia Nigro, Linda Bussini, Michele Bartoletti, Francesco Blasi, Stefano Aliberti
{"title":"鉴定社区获得性肺炎患者的耐药病原体。","authors":"Francesco Amati,&nbsp;Francesco Bindo,&nbsp;Anna Stainer,&nbsp;Andrea Gramegna,&nbsp;Marco Mantero,&nbsp;Mattia Nigro,&nbsp;Linda Bussini,&nbsp;Michele Bartoletti,&nbsp;Francesco Blasi,&nbsp;Stefano Aliberti","doi":"10.3390/arm91030018","DOIUrl":null,"url":null,"abstract":"<p><p>A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased incidence of drug-resistant pathogens (DRP) in patients from a community with pneumonia, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and <i>Pseudomonas aeruginosa</i>. Research has been published attempting to identify DRP in CAP through the implementation of probabilistic approaches in clinical practice. However, recent epidemiological data showed that the incidence of DRP in CAP varies significantly according to local ecology, healthcare systems and countries where the studies were performed. Several studies also questioned whether broad-spectrum antibiotic coverage might improve outcomes in CAP, as it is widely documented that broad-spectrum antibiotics overuse is associated with increased costs, length of hospital stay, drug adverse events and resistance. The aim of this review is to analyze the different approaches used to identify DRP in CAP patients as well as the outcomes and adverse events in patients undergoing broad-spectrum antibiotics.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 3","pages":"224-238"},"PeriodicalIF":1.8000,"publicationDate":"2023-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295768/pdf/","citationCount":"2","resultStr":"{\"title\":\"Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia.\",\"authors\":\"Francesco Amati,&nbsp;Francesco Bindo,&nbsp;Anna Stainer,&nbsp;Andrea Gramegna,&nbsp;Marco Mantero,&nbsp;Mattia Nigro,&nbsp;Linda Bussini,&nbsp;Michele Bartoletti,&nbsp;Francesco Blasi,&nbsp;Stefano Aliberti\",\"doi\":\"10.3390/arm91030018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased incidence of drug-resistant pathogens (DRP) in patients from a community with pneumonia, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and <i>Pseudomonas aeruginosa</i>. Research has been published attempting to identify DRP in CAP through the implementation of probabilistic approaches in clinical practice. However, recent epidemiological data showed that the incidence of DRP in CAP varies significantly according to local ecology, healthcare systems and countries where the studies were performed. Several studies also questioned whether broad-spectrum antibiotic coverage might improve outcomes in CAP, as it is widely documented that broad-spectrum antibiotics overuse is associated with increased costs, length of hospital stay, drug adverse events and resistance. The aim of this review is to analyze the different approaches used to identify DRP in CAP patients as well as the outcomes and adverse events in patients undergoing broad-spectrum antibiotics.</p>\",\"PeriodicalId\":7391,\"journal\":{\"name\":\"Advances in respiratory medicine\",\"volume\":\"91 3\",\"pages\":\"224-238\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295768/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in respiratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/arm91030018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/arm91030018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 2

摘要

在过去的15年里,作为社区获得性肺炎(CAP)患者的经验疗法,广谱抗生素的使用量大幅增加。导致这一现象的驱动因素之一是一些证据表明,肺炎社区患者中耐药病原体(DRP)的发病率增加,包括耐甲氧西林金黄色葡萄球菌(MRSA)和铜绿假单胞菌。已经发表了研究,试图通过在临床实践中实施概率方法来识别CAP中的DRP。然而,最近的流行病学数据显示,CAP中DRP的发病率因当地生态、医疗系统和研究所在国的不同而有很大差异。几项研究还质疑广谱抗生素覆盖率是否可以改善CAP的结果,因为有广泛的文献表明,广谱抗生素过度使用与成本增加、住院时间延长、药物不良事件和耐药性有关。这篇综述的目的是分析用于识别CAP患者DRP的不同方法,以及接受广谱抗生素治疗的患者的结果和不良事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia.

A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased incidence of drug-resistant pathogens (DRP) in patients from a community with pneumonia, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Research has been published attempting to identify DRP in CAP through the implementation of probabilistic approaches in clinical practice. However, recent epidemiological data showed that the incidence of DRP in CAP varies significantly according to local ecology, healthcare systems and countries where the studies were performed. Several studies also questioned whether broad-spectrum antibiotic coverage might improve outcomes in CAP, as it is widely documented that broad-spectrum antibiotics overuse is associated with increased costs, length of hospital stay, drug adverse events and resistance. The aim of this review is to analyze the different approaches used to identify DRP in CAP patients as well as the outcomes and adverse events in patients undergoing broad-spectrum antibiotics.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in respiratory medicine
Advances in respiratory medicine RESPIRATORY SYSTEM-
CiteScore
2.60
自引率
0.00%
发文量
90
期刊介绍: "Advances in Respiratory Medicine" is a new international title for "Pneumonologia i Alergologia Polska", edited bimonthly and addressed to respiratory professionals. The Journal contains peer-reviewed original research papers, short communications, case-reports, recommendations of the Polish Respiratory Society concerning the diagnosis and treatment of lung diseases, editorials, postgraduate education articles, letters and book reviews in the field of pneumonology, allergology, oncology, immunology and infectious diseases. "Advances in Respiratory Medicine" is an open access, official journal of Polish Society of Lung Diseases, Polish Society of Allergology and National Research Institute of Tuberculosis and Lung Diseases.
期刊最新文献
Association Between Weight-Adjusted Waist Index and Emphysema in Adults in the United States: A Cross-Sectional Study Involving 44,949 Participants. Beneficial Impact of Vaccination Against SARS-CoV-2 on the Mental Health of IPF Patients. 2024 Update on Position Statement by Experts from the Polish Society of Allergology and the Polish Respiratory Society on the Evaluation of Efficacy and Effectiveness of Single Inhaler Triple Therapies in Asthma Treatment. Application of Forced Oscillation Technique in Assessing Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Expression of Epithelial Alarmin Receptor on Innate Lymphoid Cells Type 2 in Eosinophilic Chronic Obstructive Pulmonary Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1